Table 1.
List of anti-PD-1/PD-L1 immune checkpoints inhibitors that have been approved by different government agencies.
| Drug | Indication 1 |
|---|---|
| Nivolumab (Bristol-Myers Squibb, New York, NY, USA) Anti-PD-1 |
Non-Small Cell Lung Cancer (FDA, EMA, PMDA, NMPA) Melanoma (FDA, EMA, PMDA) Renal Cell Carcinoma (FDA, EMA, PMDA) Head and Neck Cancer (FDA, EMA, PMDA) Hodgkin Lymphoma (FDA, EMA, PMDA) Oesophageal Cancer (FDA, EMA, PMDA) Bladder Cancer (FDA, EMA) Gastric Cancer (FDA, PMDA) Mesothelioma (PMDA) Colorectal Cancer (FDA) Hepatocellular Cancer (FDA) Small Cell Lung Cancer (FDA) |
| Pembrolizumab (Merck Co., Kenilworth, NJ, USA) Anti-PD-1 |
Melanoma (FDA, EMA, PMDA, NMPA) Non-Small Cell Lung Cancer (FDA, EMA, PMDA, NMPA) Renal Cell Carcinoma (FDA, EMA, PMDA) Hodgkin Lymphoma (FDA, EMA, PMDA) Bladder Cancer (FDA, EMA, PMDA) Head and Neck Cancer (FDA, EMA, PMDA) MSI-High Solid Tumours (FDA, PMDA) Merkel Cell Carcinoma (FDA, EMA, PMDA) Oesophageal Cancer (FDA, EMA, PMDA) Gastric Cancer (FDA) Hepatocellular Carcinoma (FDA) Cervical Cancer (FDA) Primary Mediastinal B-cell Lymphoma (FDA) Small Cell Lung Cancer (FDA) Endometrial Carcinoma (FDA) Cutaneous Squamous Cell Carcinoma (FDA) Triple Negative Breast Cancer (FDA) |
| Atezolizumab (Roche, Basel, Switzerland) Anti-PD-L1 |
Non-Small Cell Lung Cancer (FDA, EMA, PMDA) Small Cell Lung Cancer (FDA, PMDA) Bladder Cancer (FDA, EMA) Breast Cancer (FDA) Hepatocellular Carcinoma (FDA) Melanoma (FDA) |
| Durvalumab (AstraZeneca, Cambridge, UK) Anti-PD-L1 |
Non-Small Cell Lung Cancer (FDA, EMA, PMDA) Bladder Cancer (FDA) Small Cell Lung Cancer (FDA) |
| Avelumab (Pfizer/Merck KGaA, Darmstadt, Germany) Anti-PD-L1 |
Merkel Cell Carcinoma (FDA, EMA, PMDA) Renal Cell Carcinoma (FDA) Bladder Cancer (FDA) |
| Cemiplimab (Regeneron, New York, NY, USA) Anti-PD-L1 |
Cutaneous Squamous-Cell Cancer (FDA, EMA) Non-Small Cell Lung Cancer (FDA) Basal Cell Carcinoma (FDA) |
| Toripalimab (Junshi Biosciences, Shanghai, China) Anti-PD-1 |
Melanoma (NMPA) Nasopharyngeal Carcinoma (NMPA) |
| Sintilimab (Innovent Biologics, Hongkong, China) Anti-PD-1 |
Hodgkin Lymphoma (NMPA) Non-Small Cell Lung Cancer (NMPA) |
| Camrelizumab (Jiangsu HengRui, Lianyungang, China) Anti-PD-1 |
Hodgkin Lymphoma (NMPA) Hepatocellular Carcinoma (NMPA) |
| Tislelizumab (Beigene, Beijing, China) Anti-PD-1 |
Hodgkin Lymphoma (NMPA) Bladder Cancer (NMPA) |
| Dostarlimab (GlaxoSmithKline LLC, Wales, UK) Anti-PD-1 |
Endometrial Carcinoma (FDA) |
1 Indication for each type of tumour approved by the Food and Drugs Administration (FDA), USA; the European Medicines Agency (EMA), EU; the Pharmaceuticals and Medical Devices Agency (PMDA), Japan; and the National Medical Products Administration (NMPA), China. Data adapted from Cancer Research Institute (cancerresearch.org, last accessed 30 June 2021) [23].